B) A single dose of Nirvesimab given in December in the U.S. to a 10-month-old ex-premie with bronchopulmonary dysplasia (baby’s mother did not receive RSV vaccine)
Nirvesimab is a monoclonal antibody. A single dose is recommended for infants experiencing their first RSV season who are: < 8 months old and birth parent did not receive RSV vaccine during pregnancy or received the vaccine within 14 days of giving birth, infants experiencing their second RSV season who are: < 8 months old and didn’t receive Nirvesimab during their first season, or 8-19 months old and high-risk (bronchopulmonary dysplasia, severely immunocompromised, cystic fibrosis, American Indian or Alaskan Native). Palivizumab is the monoclonal antibody that was previously available; it is recommended only if Nirvesimab is unavailable, and is given in 5 monthly doses. RSV vaccine is recommended for adults age 60 and over and high-risk adults age 50-59 years. It is also recommended for pregnant individuals between 32 0/7 and 36 6/7 weeks gestation during September through January in the U.S. However, if RSV vaccine was received during a prior pregnancy, it is not recommended to be given again with subsequent pregnancies. RSV-IVIG is no longer available.
Loading ...
January 21, 2025 at 4:16 pm
B) A single dose of Nirvesimab given in December in the U.S. to a 10-month-old ex-premie with bronchopulmonary dysplasia (baby’s mother did not receive RSV vaccine)
Nirvesimab is a monoclonal antibody. A single dose is recommended for infants experiencing their first RSV season who are: < 8 months old and birth parent did not receive RSV vaccine during pregnancy or received the vaccine within 14 days of giving birth, infants experiencing their second RSV season who are: < 8 months old and didn’t receive Nirvesimab during their first season, or 8-19 months old and high-risk (bronchopulmonary dysplasia, severely immunocompromised, cystic fibrosis, American Indian or Alaskan Native). Palivizumab is the monoclonal antibody that was previously available; it is recommended only if Nirvesimab is unavailable, and is given in 5 monthly doses. RSV vaccine is recommended for adults age 60 and over and high-risk adults age 50-59 years. It is also recommended for pregnant individuals between 32 0/7 and 36 6/7 weeks gestation during September through January in the U.S. However, if RSV vaccine was received during a prior pregnancy, it is not recommended to be given again with subsequent pregnancies. RSV-IVIG is no longer available.